"Unleashing the Power of AI: Unimaginable Antibodies for Unprecedented Effectiveness"

LabGenius, a company in South London, is using AI-powered robotic systems and machine learning algorithms to automate the process of designing and testing medical antibodies. By exploring the vast search space of potential antibodies, the AI model can quickly identify and refine designs that can differentiate between healthy and diseased cells. The automated approach has the potential to revolutionize drug discovery, leading to more effective antibody treatments with fewer side effects. LabGenius has raised $28 million in funding and is partnering with pharmaceutical companies to offer its services.